The sixth edition of the haemophilia B database lists in easily accessible form all known factor IX mutations due to small changes (base substitutions and short additions and/or deletions of <30 bp) identified in haemophilia B patients. The 1380 patient entries are ordered by the nucleotide number of their mutation. Where known, details are given on factor IX activity, factor IX antigen in circulation and origin of mutation. References to published mutations are given and the laboratories generating the data are indicated.
The database below lists known point mutations and short deletions and additions in the factor IX gene causing the bleeding disorder haemophilia B or Christmas disease [for reviews see Roberts et al., 1993 (139) and Tuddenham & Giannelli, 1994 (180) ] These mutations result in a defective clotting factor IX, a glycoprotein of 415 amino acid residues normally present in plasma and an essential component of the clotting cascade. The disease is an X-linked inherited recessive disorder affecting one in ∼30 000 males and only very rarely females.
The purpose of this database is to update that of last year [Giannelli et al., 1994 (59) ] by collecting in an accessible, summary form molecular data on the causative mutations of haemophilia B patients worldwide. It is not intended to replace primary publications, although it does contain a significant amount of unpublished work. We have continued our database numbering system [Giannelli et al., 1991 (58) ] giving all patients a unique patient identity number (PIN or ID number). As in previous years, we have included repeat observations of the same mutation, as well as molecularly unique mutations, but in order to keep the main table to a manageable size we have deleted from the table all the repeats of molecular events. Such events are entered in the table only once, but the FIX:C and FIX:Ag entries show the average of the factor IX values associated with these mutations. The comments relevant to each group of mutations are summarized and a full list of references is given. The central coordinators will keep the data relative to the excluded mutations in a separate file that will be available on request.
The factor IX gene lies on the long arm of the X chromosome at Xq27.1 and its entire sequence of 33 kb is known [Yoshitake et al., 1985 (195) ]. It contains eight exons (a-h) encoding six major domains of factor IX. (i) Exon a, encoding a hydrophobic signal peptide which targets the protein for secretion from the hepatocyte into the blood stream. (ii) Exons b and c, encoding a propeptide and a gla domain, the latter containing 12 γ-carboxyglutamyl residues. This post-translational modification is required for correct folding of and calcium binding by factor IX. (iii) Exon d, encoding a type B or first epidermal growth factor-like domain, which shows homology to epidermal growth factor (EGF) and, in addition, contains conserved carboxylate residues, including a β-hydroxyaspartate at amino acid 64. This domain binds an additional Ca 2+ with high affinity [Handford et al., 1991 (69) ]. (iv) Exon e, encoding a type A or second epidermal growth factor-like (EGF) domain, which lacks the conserved carboxylate residues of the EGF type B domain. (v) Exon f, encoding an activation domain, within which factor XIa and VIIa plus tissue factor cleave twice, converting factor IX to IXa. (vi) Exons g and h, encoding the serine protease or catalytic domain, responsible for the proteolysis of factor X to Xa. This region is homologous to other well-studied serine proteases (e.g. chymotrypsin) and it is thought likely that His221, Asp269 and Ser365 all participate in the classical catalytic mechanism.
Factor IX is initially synthesized in the liver as a precursor molecule, either 46, 41 or 39 amino acids [it is not known which, * To whom correspondence should be addressed although 39 is probable; Pang et al., 1994 (120) ] longer at its N-terminus than the 415 amino acid mature factor IX found in plasma. Processing steps occur in the hepatocyte prior to secretion and sequentially remove the hydrophobic signal peptide and the propeptide. In addition to γ-carboxylation of the 12 N-terminal glutamyl residues carried out by a vitamin K-dependent carboxylase and the partial β-hydroxylation of Asp64, N-linked carbohydrate side chains are added at residues 157 and 167 and O-linked carbohydrates at Ser53, Ser61, Thr159 and Thr169 [Hase et al., 1994 (71) ; Nishimura et al., 1992 (118) ; Agarwala et al. 1994 (196)] There are 1380 patient entries in this sixth edition of the database, compared with 1142 patients last year [Giannelli et al., 1994 (59) ]. Besides point mutants, it includes 113 short (defined as <30 nt) deletions or additions or both, made up of 86 deletions, 21 additions and six examples involving both additions and deletions. There are also 18 double mutations, one triple mutation, 14 inhibitor patients, two somatic mosiacs and 21 females (either affected or non-symptomatic carriers). The list excludes 29 patients with partial or complete gene deletions or more complex rearrangements [Thompson, 1990 (168) ] and others observed since [Ketterling et al., 1994 (80,81) ; Saad et al., 1994 (142) ]. Of the 1380 patients studied, 552 show unique molecular events probably causing the disease, while the remainder are repeats. As is well known, many of these repeats occur at CG doublets and involve a CG→TG or CA change. As discussed before [Giannelli et al., 1994 (59) ], such mutants are believed to be genuine 'hot spots' for mutation. However, it is now becoming clear that the high number of repeat observations at some CG doublets (e.g. 71 examples at nt 31 008) are caused, at least in part, by a founder effect. A founder effect is now well established [Thompson et al., 1994 (174) ; Bottema et al., 1990b (16) ] for a mutation at a residue other than CGs (e.g. 31 examples at nt 31 311) and there are many examples in the database of repeating mutations. Probably many, but not all, of these will have a common origin.
We have continued to include information in the comments section on new (or de novo) mutations where known. In addition, we note whether the mutation occurred in the mother or in the maternal grandfather or grandmother. Two coordinators have also included the age of the parent of the child carrying or affected by the mutant gene. Because not all coordinators list new mutations and such data is incomplete, this database cannot be usefully analysed for the frequency of such new mutations.
The distribution of mutants according to protein domains and control regions within the gene shows that mutations have been detected in all regions except the poly(A) site. Remarkably, there are now 17 molecularly unique mutants occurring within a short region of the promoter and these are invaluable in studying gene regulation [Crossley et al., 1992 (35) ; Picketts et al., 1993 (122) ; Reijnen et al., 1993 (132) ]. Missense mutations within exons give valuable information as to the importance of particular amino acid residues. The present list contains 333 different amino acid substitutions (probably detrimental). Ninety five residues of factor IX show two or more amino acid substitutions. These include the active site Ser365 and the proposed active site Asp269, but none is yet known for the proposed active site His221. Mutations at nine of the 12 γ-carboxyglutamyl residues have now been detected, confirming their critical role for the function of factor IX. Amino acid substitutions have also been found at all of the 22 cysteines of circulating factor IX and therefore mutations have been found that compromise each one of the disulphide bridges of the mature protein, thus confirming the importance of such structures. This year 224 missense mutations were added, of which 43 are new.
The fourth (1993) edition of this database is now available on the Internet. It can be reached on ftp://ftp.ebi.ac.uk/pub/databases/haemb/. The format used in the 1993 file server version of the database is somewhat related to that used for the familiar EMBL nucleic acid sequence database and should allow easy computer searching for particular features. The new entries in the sixth edition of the database will be available by the end of 1995.
The database was compiled by the central coordinators (Giannelli and Green) from separate lists updating the previous year's list prepared by coordinators for the different countries. This year these were as follows: Giannelli and Green representing the UK, Sweden and Iceland; Sommer representing the USA; Poon representing Canada; Ludwig and Schwaab representing Germany; Reitsma representing The Netherlands; Goossens representing France; Yoshioka representing Japan; Brownlee, the rest of the world. New data or notification of errors or omissions should be sent to the individual country coordinators. This database, including all repeated mutations, is available from individual country coordinators on floppy discs in WordPerfect 5.1 and dBase formats.
